Pneumocystis jirovecii pneumonia primary prevention

Pneumonia Main Page
Pneumocystis jirovecii pneumonia Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Pneumocystis jirovecii pneumonia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Chest X Ray
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Pneumocystis jirovecii pneumonia primary prevention On the Web
Most recent articles
cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Pneumocystis jirovecii pneumonia primary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Pneumocystis jirovecii pneumonia primary prevention
CDC on Pneumocystis jirovecii pneumonia primary prevention
Pneumocystis jirovecii pneumonia primary prevention in the news
Blogs on Pneumocystis jirovecii pneumonia primary prevention
Pneumocystis jirovecii pneumonia
Risk calculators and risk factors for Pneumocystis jirovecii pneumonia primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Primary Prevention

In immunocompromised patients (e.g. cancer patients on chemotherapy, or persons living with AIDS with a CD4+ T-cell count below 200/μl), prophylaxis with co-trimoxazole or regular pentamidine inhalations may help prevent PCP. Preventive therapy is recommended for:

• Patients with AIDS who have CD4 counts below 200
• Bone marrow transplant recipients
• Organ transplant recipients
• People who take long-term, high-dose corticosteroids
• People who have had previous episodes of this infection